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Background: Isolated fucoidans from brown marine algae have been shown to have a range 
of immune-modulating effects. This exploratory study aimed to determine whether a seaweed 
nutrient complex containing a blend of extracts from three different species of brown algae 
plus nutrients is safe to administer and has biological potential as an immune modulator. The 
study was undertaken as an open-label combined Phase I and II study.
Methods: Participants (n = 10) were randomized to receive the study medication at either a 
100 mg (n = 5) or 1000 mg (n = 5) dose over 4 weeks. The primary outcome measurement was 
in vivo changes in lymphocyte subsets. The secondary outcome measures were ex vivo changes 
in T-lymphocyte (CD4 and CD8) activation, phagocytosis of granulocytes and monocytes, 
T helper 1/T helper 2 cytokines, and serum oxygen radical absorbance capacity.
Results: The preparation was found to be safe over the 4 weeks at both doses tested. There 
were no clinically relevant changes to blood measurements of hemopoietic, hepatic, or renal 
function. Immunomodulatory measurements showed no dose response between the two doses. 
The combined results from the two doses demonstrated a significant increase in cytotoxic 
T cell numbers and phagocytic capacity in monocytes, and a significant decrease in levels of 
the inflammatory cytokine interleukin 6. A separate analysis of the 100 mg dose (n = 5) alone 
showed a significant linear component over time (P , 0.05) for phagocytosis by both granu-
locytes and monocytes.
Conclusion: The seaweed nutrient complex was safe to use when taken orally over 4 weeks. 
The preparation was demonstrated to have potential as an immune modulator, and this bioactiv-
ity deserves further exploration.
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Background
Marine algae have been used by humans as both a food and a medicine for thousands 
of years.1,2 The populations of Japan and Korea consume seaweed or ‘macroalgae’ 
every day, with daily consumption averaging 14.2 g in Japan3 and 6.6 g in Korea.4 
A recent epidemiological study in Japan found that dietary seaweed was associated 
with lowered all-cause mortality and lower mortality from lung cancer for men and 
women, from pancreatic cancer for men, and from cerebrovascular disease for   women.5 
In pregnant Japanese women, dietary intake of seaweed has been associated with a 
decreased prevalence of allergic rhinitis.6 Although it is not considered a common 
part of Western diets, people in Western societies regularly ingest alginates and car-
rageenans derived from macroalgae as a component of foods, and therapeutic mac-
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for their iodine content.1,2 Commonly used dietary seaweeds 
include Undaria pinnatifida (wakame),7 Porphyra species 
(nori),8 Laminaria species (kelp, kombu),9 Palmaria palmata 
(dulse),10 and Fucus vesiculosus (bladder wrack).11
Fucoidans are considered to be one of the main thera-
peutic components of brown algae12 and constitute up to 
25%–30% of the algae dry weight, depending on the specific 
seaweed species and, to a lesser extent, on season variation at 
time of harvesting.13 Structurally, the fucoidans are composed 
of sulfated homo- and heteropolysaccharides (including 
polysaccharides with a high content of glucuronic acid and a 
low content of fucose and sulfates) as well as polysaccharides 
built as sulfated homopolymers of fucose.13 In addition to 
fucose, they also contain other monosaccharides (eg, man-
nose, galactose, glucose, xylose), uronic acids, acetyl groups, 
and protein.12 The range of fucoidan structures is extremely 
diverse, as brown algae synthesize highly branched polysac-
charides with species-specific sugar compositions. In addi-
tion, every species produces multiple types of fucoidans that 
can differ in the proportion of monosaccharide moieties.13
Brown marine algae in the form of seaweed extracts have 
been shown in animal studies to have a marked antitumor 
effect when delivered either intravenously or orally, an effect 
partly attributed to the stimulation of both innate and specific 
immunity.14–17 Isolated fucoidans from brown algae have been 
shown to have a range of immune-modulating effects. Ex vivo, 
Fucus-derived fucoidan had immunostimulating and maturing 
effects on bone marrow-derived dendritic cells, perhaps via the 
modulation of nuclear factor-kappa B (NF-κB).18 In human 
monocyte-derived dendritic cells, fucoidan increased levels 
of tumor necrosis factor alpha (TNF-α), interferon gamma 
(IFN-γ), and interleukin 12 (IL-12). When naive T cells were 
stimulated by the fucoidan-treated dendritic cells, they differ-
entiated towards a helper T cell type 1 (Th1).19   Fucus-derived 
fucoidan has been shown to stimulate the enzyme granzyme A, 
which is believed to induce the production of cytokines in 
a variety of cells, and may in part explain the immune-
  modulating mechanism of fucoidans.20
In animal studies, intravenously administered Fucus-
derived fucoidan was observed to have a potent, long-lasting 
mobilizing effect on hemopoetic stem cells when injected 
into mice21,22 or primates.22 These cells replenish the immune 
cells in tissues and organs. In a mouse model, Cladosiphon-
derived fucoidan downregulated IL-6 (a Th2 cytokine) and 
ameliorated colitis.23 Other studies in mice have observed 
immunomodulatory effects chiefly by increasing the activ-
ity of natural killer (NK) cells and via a modulation of the 
Th1:Th2 ratio.24,25
In human studies, low levels of serum uptake of fucoidans 
were observed after ingestion of Undaria fucoidan, deter-
mined by using a novel antibody raised against sulfated 
polysaccharides.26 When this fucoidan was ingested over 
12 days, it increased the amount of the chemokine stromal 
cell-derived factor 1 and also the number of chemokine recep-
tor CXCR4-expressing hemopoetic stem cells. The levels of 
the chemokine IFN-γ also increased.27
The toxicity of seaweed extracts is generally very low. 
There were no toxicological changes observed in rats given 
up to 300 mg/kg orally of fucoidan from Laminaria japonica. 
Anticoagulant effects were observed at doses of 900–
2500 mg/kg, but no other signs of toxicity were observed.28 
A polyphenol-rich fraction of Fucus was also shown to lack 
acute toxic effects in rats after 4 weeks of oral dosing.29
We have recently demonstrated that a seaweed nutrition 
complex (containing a blend of extracts from three different 
species of brown algae plus nutrients zinc, manganese, and 
vitamin B6) has marked bioactivity in reducing the symptoms 
of osteoarthritis of the knee.30 To date, the mechanism of 
action for this effect is unknown. In this study, we examined 
the effects of the same preparation on the immune function 
of healthy individuals using an open-label design at two 
doses to determine immunomodulatory effects. This was a 
combined Phase I and II study aimed at determining acute 
safety and efficacy.
Methods
research design
This trial was an exploratory study conducted as an open-
label dosing study, with two different doses randomized 
to participants, conducted in 2008 over 4 weeks (28 days) 
in Lismore, a regional city in northern New South Wales 
(Australia). The study was approved by the Human Research 
Ethics Committee of Southern Cross   University (Ethics 
approval number: ECN-07-36). The research was con-
ducted in compliance with Good   Clinical Practices and in 
accordance with the guidelines of the   Australian National 
Health and Medical Research Council and the Declaration of 
Helsinki (as revised in 2004). The trial was registered with 
the Australian and New Zealand Clinical Trials Register 
(ACTRN12607000228482).
Participants
A convenience sample of healthy individuals aged between 
18 and 65 years was recruited by email from staff and stu-
dents at Southern Cross University, and from Lismore and 
surrounding areas through newspaper advertising, regional Biologics Targets & Therapy 2011:5 submit your manuscript | www.dovepress.com
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radio, and television. All participants received a study 
information sheet outlining the study and signed an informed 
consent form agreeing to participate.
A sample size of 10 participants was based on data from 
previous work undertaken at Southern Cross University on 
the number required in a pilot study to demonstrate changes 
in immune parameters.
Participants were included if they were healthy, had 
neither an acute nor a chronic medical condition, and were 
nonsmokers. Participants were excluded if they were taking 
antioxidant medications and/or other dietary supplements; 
had poor venous access; had a history of any autoimmune dis-
orders or diabetes; were taking nonsteroidal anti-inflamma-
tory drugs, immune suppressant drugs, cytokines, interferon, 
echinacea, or other immune-stimulating herbs; had clinically 
abnormal liver function tests at baseline; developed a cold 
or other acute upper respiratory tract infection or influenza 
during the course of the study; were unwilling to have blood 
taken three times during the study; or were unwilling to 
comply with the study protocols.
Outcome measurements
Safety was assessed by actively monitoring adverse events and 
by a full blood count, liver function tests, and determination 
of urea, creatinine, electrolytes, cholesterol, and triglycerides 
taken at the first baseline measurement and at the conclusion 
of the study to assess toxicity to the hemopoietic, hepatic, 
and renal systems. Vital signs (pulse and blood pressure) and 
weight were also monitored at every measurement point.
The primary efficacy outcome measurements were in vivo 
changes in lymphocyte subsets (mature T cells [CD3+], B 
cells [CD19+], helper T cells [CD3+, CD4+], cytotoxic T 
cells [CD3+, CD8+], and NK cells [CD3-CD16+ and/or 
CD56+]). The secondary outcome measures were ex vivo 
changes in T-lymphocyte (CD4, CD8) activation, phagocy-
tosis by granulocytes and monocytes, T helper 1/T helper 2 
cytokines (IFN-γ, TNF-α, IL-10, IL-6, IL-4, IL-2), and serum 
oxygen radical absorbance capacity.
Efficacy measurements were taken at day 1 (baseline), 
day 3, and day 28. Three measurements were taken in total, 
and participants attended three clinics during which weight, 
blood pressure, pulse rate, and concomitant medication use 
were recorded and fasting blood samples collected.
Subjects returned all remaining capsules at each clinic, 
and these were counted as a measure of compliance. The 
investigator maintained an inventory record of all capsules 
received and dispensed. It was assumed that capsules not 
returned were taken.
Participants were asked at the end of the study to evaluate 
the study medication by answering a question indicating 
their satisfaction, dissatisfaction, or neither satisfaction nor 
dissatisfaction with the study medication.
study medication and dose
The study medication used Maritech® extracts (Marinova Pty 
Ltd, Hobart, Australia), which contains novel fucoidan-rich 
extracts of seaweeds and which are manufactured using a 
proprietary aqueous process that produces largely unaltered 
fucoidan fractions. They are complex ‘whole plant’ extracts 
that in addition to a substantial fucoidan concentration also 
contain significant levels of bioactive seaweed polyphenols 
(polyphloroglucinols) associated with the fucoidan molecule. 
In this study, we used a blend of three Maritech® extracts 
from different species of brown seaweeds: Maritech® Fucus 
vesiculosis (85% w/w), Maritech® Macrocystis pyrifera 
(10% w/w), and Maritech® Laminaria japonica (5% w/w). 
In addition, vitamin B6, zinc sulfate, and manganese sulfate 
were included in the formulation, as detailed in Table 1. The 
study medication was manufactured as 100 mg and 250 mg 
capsules (Gel Caps) under the code of Good Manufacturing 
Practice. The total fucoidan concentration in the 100 and 
250 mg capsules was 75 and 187.5 mg, respectively.
Subjects were randomized to either a 100 or 1000 mg 
dose  group  using  the  research  randomizer  website 
(www.randomizer.org). Five sets of two numbers per set, using 
a range of one to two, were generated. These numbers were 
used to assign the participants to either the 100 or 1000 mg 
dose. The 100 mg dose was delivered in one 100 mg gel capsule 
daily (taken in the morning) to five participants. The 1000 mg 
dose was delivered as four 250 mg capsules daily (two capsules 
taken twice daily) to five participants. The capsules were self-
administered orally by the participants after food.
Laboratory assays
Lymphocyte subsets
Blood was collected in ethylene diamine tetra-acetic acid 
(EDTA) tubes (4 mL of blood per participant), stored at room 
temperature, and analyzed within 24 hours of collection. 
Table 1 contents of Maritech® extract capsules
Component 100 mg 250 mg
Maritech® Fucus vesiculosis 85 mg 212.5 mg
Maritech® Macrocystis pyrifera 5 mg 12.5 mg
Maritech® Laminaria japonica 10 mg 25 mg
Pyridoxine hydrochloride 57.5 mg 14.38 mg
Zinc sulfate monohydrate 25 mg 6.25 mg
Manganese sulfate 4 mg 1 mgBiologics Targets & Therapy 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
48
Myers et al
Flow cytometric analysis was used for the quantitation of 
T cells (including helper and suppressor subsets), B cells, 
and NK cells. Staining of peripheral blood leukocytes was 
performed by the lyse/no wash method using MultiTest IMK 
kit reagents (catalogue no. 340503, Becton Dickinson, San 
Jose, CA, USA).
Fifty microliters of whole blood (EDTA) was added 
to 20 µL of both fluorochrome-conjugated monoclonal 
antibodies (anti-CD3fluoresceinisothiocyanate [FITC]/
CD8phycoerythrin [PE]/CD45peridinin chlorophyll protein 
[PerCP]/CD4allo-phycocyanin [APC] and anti-CD3FITC/
CD [16 + 56] PE/CD45PerCP/CD19 APC). Tubes were 
vortexed and incubated for 15 minutes in the dark at 
room temperature. Four-hundred and fifty microliters of 
1 × MultiTest Lysing Solution was added to each tube, 
vortexed, and incubated for 15 minutes in the dark at room 
temperature.
Analysis was carried out on a four-color FACSCalibur 
Flow Cytometer and MultiSET Software (Becton Dickinson) 
using excitation wavelengths of 488 and 635 nm.
T cell activation
Lithium heparinized blood (4 mL per participant) was 
stored at room temperature and analyzed within 8 hours of 
collection. Lymphocyte activation was measured on whole 
blood according to the expression of an early activation 
marker (CD69) in T cells stimulated with phytohemag-
glutinin (PHA-M) (Phaseolus vulgaris, Sigma L2646, 
Sigma-Aldrich, St Louis, MO, USA). This was achieved 
using FastImmune T-cell Value Bundle II (catalogue no. 
340408, Becton Dickinson) and flow cytometry to determine 
the population of activated T cells.
In brief, 5 µL of 1 mg/mL PHA-M was added to 495 µL 
of whole blood, vortexed, and incubated for 4 hours at 37°C 
(5% CO2). Unstimulated controls were run in parallel for each 
participant. Aliquots (50 µL) of preincubated blood were then 
added to 10 µL of fluorochrome-labeled monoclonal antibod-
ies (anti-γ1FITC/γ1PE/CD3PerCP, anti-CD4FITC/CD69PE/
CD3PerCP, and anti-CD8FITC/CD69PE/CD3PerCP) in 
three separate tubes. The tubes were mixed and incubated for 
15 minutes at room temperature in the dark. Four-hundred 
and fifty microliters of 1 × FACS Lysing Solution was added 
to each tube, vortexed, and incubated for 15 minutes in the 
dark at room temperature.
The percentage of T cells (total T cells, CD4 + T cells, and 
CD8 + T cells) expressing CD69 was then determined using 
a four-color FACSCalibur Flow Cytometer and CellQuest 
Pro Software (Becton Dickinson).
Phagocytosis
Lithium heparinized blood (4 mL per participant) was stored 
at room temperature and analyzed within 8 hours of col-
lection. Blood samples were assayed for granulocyte and 
monocyte phagocytic activity (post E. coli stimulation) by 
flow cytometry using the Phagotest kit (Orpegen Pharma 
10-0100, Heidelberg, Germany).
Aliquots (100 µL) of blood were precooled in an ice bath 
for 10 minutes. Each was spiked with 20 µL of FITC-labeled 
E. coli (diluted in saline to equivalent 5 × 106 bacteria), 
gently vortexed, then incubated at 37°C, and 0°C controls 
remained on ice. Activity was stopped by placing all tubes 
on ice simultaneously after 5 minutes of incubation. Cells 
were quenched (externally), washed, and red cells lysed using 
the solution provided in the kit. DNA stain solution (200 µL) 
was added to each tube to allow differentiation between free 
E. coli and human leukocytes.
For each sample, the percentage of phagocytes (granu-
locytes and monocytes) that had ingested the fluorochrome-
labeled bacteria (E. coli) was determined using a Becton 
Dickinson FACSCalibur Flow Cytometer.
Th1Th2 cytokine secretion
Lithium heparinized blood (4 mL per participant) was stored 
at room temperature and stimulated within 8 hours of collec-
tion. Cytokine secretion of blood, post ex vivo stimulation 
with PHA-M, was measured in plasma using the human Th1/
Th2 Cytokine (CBA) Kit II (Becton Dickinson, catalogue 
no. 551809).
In brief, 5 µL of 1 mg/mL PHA-M (Phaseolus vulgaris, 
Sigma L2646) was added to 495 µL of whole blood, vortexed, 
and incubated for 4 hours at 37°C (5% CO2). Unstimulated 
controls were run in parallel for each participant, and then 
vortexed and centrifuged for 5 minutes at 1500 g (room 
temperature), plasma was removed, and the samples stored 
at −80°C. Stored plasma samples were thawed, vortexed, 
and centrifuged (5 minutes, 3000 g, room temperature) 
immediately prior to analysis.
The cytokine profiles (IFN-γ, TNF-α, IL-10, IL-6, IL-4, 
IL-2) were determined for each sample using the standard 
CBA Kit protocol, which employs a series of capture beads 
with discrete fluorescence intensities to detect multiple cytok-
ines in plasma. The samples were analyzed using a four-color 
FACSCalibur Flow Cytometer and CBA software.
Oxygen radical absorbance capacity (OrAc)
Clotted blood (5 mL per participant) was centrifuged for 
5   minutes at 1500 g, serum removed, and stored at −80°C. Biologics Targets & Therapy 2011:5 submit your manuscript | www.dovepress.com
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Stored serum samples were thawed, vortexed, and centrifuged for 
3 minutes at 10,000 g at room temperature prior to analysis.
The test sera were pretreated with 0.5 M perchloric acid 
(Sigma) and centrifuged for 3 minutes at 10,000 g at room 
temperature. Supernatants from each sample were serially 
diluted with 75 mM phosphate buffer (pH 7.4) (Sigma) to 
give a dilution series of 1/8, 1/16, 1/32, and 1/64. Trolox 
(vitamin E analog) (Fluka, Buchs, Switzerland) and epicat-
echin (Sigma) were also diluted and run as a standard and 
control, respectively, with equivalent final concentrations 
of perchloric acid. Ten microliters of fluorescein (6.0 × 10–7 
M) (Sigma) and 170 µL 2, 2′-azobis (2-amidinopropane) 
dihydrochloride (AAPH) (Wako, Richmond, VA, USA) 
were added to each 20 µL test sample, Trolox standard, 
and epicatechin control dilution in a 96-well microplate 
(Greiner, Frickenhausen, Germany). Fluorescence and blank 
controls were also run. Hydrophilic ORAC, assessed as the 
ability to protect fluorescein against AAPH degradation and 
standardized against Trolox, was measured using a Wallac 
Victor2 plate reader and expressed as Trolox equivalents 
(µmol TE/L).
statistical methods
Blood safety measures, which included hematology and 
blood biochemistry measures, and lipid profile measures 
were analyzed by repeated-measures analysis with the within-
subject time (day 1, day 28) main effect, the between-subject 
treatment (100 mg, 1000 mg) effect, and time by treatment 
interaction. The multivariate Wilks’ lambda statistic was 
used to assess the significance of effects involving time (main 
effect and interaction), and the treatment effect main effect 
was assessed with the univariate F test.
Repeated-measures analysis of variance was conducted 
over the three measurement times (day 1, day 3, and day 28) 
for all immune function measures, including serum ORAC, 
and the model included the within-subject (repeated) time 
effect (day 1, day 3, day 28), the between-subject treatment 
main effect (100 mg, 1000 mg), and the time by treatment 
interaction. The multivariate Wilks’ lambda statistic was used 
to assess the significance of effects involving time (main 
effect and interaction) and the treatment effect main effect 
was assessed with the univariate F test. When any significant 
effects were present, Bonferroni-adjusted pairwise multiple 
comparisons were conducted to determine significant dif-
ferences. In the case of significant multivariate time effects, 
decomposition into the linear and quadratic time components 
was also considered with treatments combined and/or treated 
separately. Where the linear decomposition occurred, univari-
ate time effects when the sphericity assumption held were 
also presented. Treatments were considered separately if it 
appeared that either one of the treatments may have indicated 
a beneficial effect (all means increasing or decreasing).
SPSS version 15 was used for all analyses, and the sig-
nificance level was set to P = 0.05; however, as this was a 
pilot study, significance tests that resulted in P , 0.1 have 
also been highlighted.
Results
study participants
The study screened 15 volunteers and subsequently enrolled 
10 people who met the inclusion/exclusion criteria. All 10 par-
ticipants completed the study and comprised nine females (mean 
age [±SD] 33.4 years [±9.36]) and one male (age 45 years). 
Five participants received the formulation in doses of 100 mg, 
and five received 1000 mg. There was a 95% compliance with 
participants taking 1000 mg daily, and 97.14% compliance in 
individuals taking 100 mg per day. The study medication was 
well tolerated, as all 10 participants evaluated their experience of 
taking the study medication as neither satisfied nor dissatisfied 
(they did not notice benefits or adverse effects).
The mean (±SD) ages (years) of 33.6 (10.78) and 31.4 
(9.58) for the 100 and 1000 mg arms, respectively, were 
not statistically different. Baseline means, standard devia-
tions, minima and maxima for blood pressures, weight, and 
pulse rate for participants in each of the two study arms are 
reported in Table 2.
Only systolic blood pressure (P = 0.009) differed at base-
line between the two treatments, with the 100 mg treatment 
Table 2 Baseline blood pressure, weight, pulse rate: means (±sD) minima and maxima by treatment arm
Baseline  100 mg 1000 mg
N Mean SD Min Max N Mean SD Min Max
BPs (mmhg) 5 124.60 4.56 118 129 5 113.00 6.00 104 120
BPD (mmhg) 5 74.80 9.42 62 87 5 72.00 5.15 67 80
Weight (kg) 5 65.40 9.61 53 75 5 67.400 9.50 57 81
Pulse rate (per min) 5 71.60 14.79 56 94 5 60.00 9.70 48 70
Abbreviations: BPD, diastolic blood pressure; BPs, systolic blood pressure; max, maximum; min, minimum; sD, standard deviation.Biologics Targets & Therapy 2011:5 submit your manuscript | www.dovepress.com
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group having an average systolic blood pressure mean of 
124.6 (±4.56) mmHg significantly higher than the 1000 mg 
treatment group mean 113 (±6.00) mmHg.
safety
The reports of adverse events were mild and self-limiting; 
however, the two participants who experienced an adverse 
event (hay fever n = 1; head cold n = 1) took one dose of 
Ibuprofen (a nonsteroidal anti-inflammatory agent) on the 
last day of the fourth week of the study. The adverse events 
occurred in the last 2 days of the study and were not consid-
ered to be related to the medication.
The descriptive statistics for blood safety measures (full 
blood count, liver function tests, and determination of urea, 
creatinine, electrolytes, cholesterol, and triglycerides) on 
days 1 and 28 are presented in Tables 3 and 4. The results 
of the repeated-measures analysis of variance using two 
measurement times (day 1 and day 28) with P-values for 
the time, treatment, and time by treatment effects are out-
lined in Tables 5 and 6. The only significant effect in these 
analyses was a significant treatment effect for potassium 
(P = 0.035), but the change was small and well within the 
clinical reference range so was assessed as not of clinical 
significance. Interestingly, the outcome measure for the 
cholesterol ratio showed near-significant beneficial change 
over time (P , 0.10).
immune function
The descriptive statistics for the lymphocyte subsets, phago-
cytic activity of monocytes and granulocytes, and cytokines 
on days 1, 3, and 28 are presented in Table 7. Only granu-
locyte levels (P = 0.025) differed at baseline between the 
two treatments, with the 100 mg treatment group having 
significantly lower mean levels (50.9% ± 4.43%) than the 
1000 mg treatment group (59.87% ± 5.73%).
The results of the repeated-measures analysis of variance 
conducted over the three measurement points (day 1, day 3, 
and day 28) as the significance values (P-values) of the effects 
of time, time by treatment interaction, and treatment main 
effect for each of the immune function outcome measures 
are presented in Table 8. Only day 3 and day 28 measure-
ments for IL-4 were used in the repeated-measures analysis 
of variance due to the absence of variation at day 1 (all 
scores were zero).
None of the time by treatment effects was significant 
(P . 0.05), nor was any treatment main effect significant. 
However, the outcome measures of B cells (CD19), cytotoxic 
T cells, monocyte phagocytosis, and IL-6 showed a signifi-
cant change over time (P , 0.05). Granulocyte phagocytosis 
demonstrated a significant increase over time (P = 0.038) and 
a near-significant difference between treatments averaged 
over time (P = 0.06). T cells, activation of CD4, activation 
of CD8, NK cells, and IL-2 showed near-significant changes 
over time (P , 0.1). IFN-γ and TNF-α, as well as granulocyte 
phagocytosis, showed near-significant changes (P , 0.1) 
between treatments averaged over time.
Estimated time means (combined over treatments) and 
results of Bonferroni-adjusted pairwise comparisons for 
the significant time responses of B cells (CD19), cytotoxic 
T cells, monocyte phagocytosis, and IL-6 are reported in 
Table 9, and time by treatment means are graphically rep-
resented in Figure 1. For these immune function outcomes, 
the significant time effect always resulted in a significant 
difference between days 1 and 28. B cells and IL-6 decreased 
significantly over time (P = 0.003, P = 0.011, respectively), 
cytotoxic T cells increased (day 3) then decreased to day 28, 
and monocytes increased significantly from day 1 to day 28 
(P = 0.002). A common pattern can be observed across sev-
eral measures (eg, NK cells for 100 mg in Table 7) in which 
there is an increase to day 3 and a decrease by day 28, echoing 
the data for cytotoxic T cells.
Estimated means for granulocyte phagocytosis by each 
treatment by time and combined treatment by time, as well 
as treatment averaged over time (combined), are presented 
together with the results of the Bonferroni-adjusted pair-
wise comparisons over time in Table 10 with graphical 
representations in Figure 2. There was a significant mul-
tivariate time effect (P = 0.038) with a near-significant 
univariate time effect (P = 0.070), which decomposed into 
a significant linear time contrast (P = 0.008) and a nonsig-
nificant quadratic contrast (P = 0.759) for the treatments 
when considered together. Post hoc tests were consistent 
with this linear trend, with day 28 being significantly 
higher than day 1 (P = 0.025). When the two treatments 
were analyzed separately, the multivariate and univariate 
time effects were nonsignificant for each of the treat-
ments (P = 0.125 and P = 0.147, respectively, for 100 mg, 
and P = 0.164 and P = 0.288, respectively, for 1000 mg), 
but there was a significant linear contrast for the 100 mg 
treatment (P = 0.038) and a nonsignificant linear contrast 
for the 1000 mg treatment (P = 0.146). In considering the 
near-significant treatment effect (the difference between 
treatments), the 100 mg treatment mean was lower (not 
significantly, P = 0.06) than 1000 mg.
As the data suggested that phagocytosis by monocytes 
and granulocytes and IL-6 behaved in a beneficial manner 
with the 100 mg treatment, separate repeated-measures anal-
yses were performed on these immune response variables Biologics Targets & Therapy 2011:5 submit your manuscript | www.dovepress.com
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Table 3 Blood safety: means, sD, minima, and maxima by treatment arm and measurement occasion
Measure 100 mg 1000 mg
N Mean SD Min Max N Mean SD Min Max
Hematology day 1
red cell count (×1012/L) 5 4.5 0.2 4.3 4.9 5 4.3 0.3 4.0 4.7
hemoglobin (g/L) 5 138.2 6.7 129.0 147.0 5 133.6 9.0 123.0 143.0
hematocrit (%) 5 0.41 0.02 0.39 0.44 5 0.40 0.02 0.37 0.42
Mean corpuscular volume (fL) 5 92.0 2.9 89.0 96.0 5 91.8 1.9 90.0 95.0
White cell count (×109/L) 5 6.1 1.7 4.6 8.9 5 6.1 0.5 5.5 6.9
Lymphocytes (×109/L) 5 2.2 0.3 2.0 2.6 5 1.9 0.3 1.7 2.4
Monocytes (×109/L) 5 0.4 0.1 0.3 0.5 5 0.5 0.2 0.3 0.8
neutrophils (×109/L) 5 3.4 1.5 2.2 5.9 5 3.4 0.4 3.0 4.0
Basophils (×109/L) 5 0.0 0.1 0.0 0.1 5 0.0 0.0 0.0 0.0
eosinophils (×109/L) 5 0.1 0.1 0.1 0.3 5 0.2 0.1 0.1 0.4
Platelets (×109/L) 5 300.0 22.6 277.0 337.0 5 287.4 79.3 199.0 369.0
Biochemistry day 1
Alkaline phosphatase (µ/L) 5 54.2 11.2 41.0 64.0 5 57.0 9.8 44.0 69.0
serum alanine aminotransferase (µ/L) 5 12.8 3.1 10.0 18.0 5 13.4 4.5 8.0 20.0
Aspartate aminotransferase (µ/L) 5 19.0 3.8 15.0 25.0 5 18.6 2.4 16.0 21.0
gamma glutamyl transferase (µ/L) 5 14.8 5.4 9.0 23.0 5 13.6 2.1 12.0 17.0
Bilirubin (µmol/L) 5 10.8 2.8 7.0 14.0 5 10.8 3.0 6.0 14.0
Protein (g/L) 5 67.4 3.4 64.0 72.0 5 69.0 2.9 66.0 73.0
Albumin (g/L) 5 44.6 2.3 42.0 48.0 5 44.0 2.8 41.0 47.0
sodium (mmol/L) 5 138.6 1.3 137.0 140.0 5 138.8 0.4 138.0 139.0
Potassium (mmol/L) 5 3.7 0.1 3.6 3.9 5 4.1 0.4 3.7 4.7
chloride (mmol/L) 5 106.4 1.3 105.0 108.0 5 106.0 1.6 104.0 108.0
BUn/urea (mmol/L) 5 3.9 1.1 2.7 5.2 5 4.0 1.1 2.7 5.8
creatinine (mmol/L) 5 71.0 7.5 64.0 80.0 5 77.0 11.7 66.0 97.0
Hematology day 28
red cell count (×1012/L) 5 4.3 0.3 3.8 4.6 5 4.2 0.4 3.6 4.5
hemoglobin (g/L) 5 136.0 10.2 118.0 143.0 5 131.8 10.9 114.0 141.0
hematocrit (%) 5 0.40 0.03 0.35 0.42 5 0.39 0.03 0.34 0.41
Mean corpuscular volume (fL) 5 92.0 2.3 90.0 95.0 5 92.0 1.9 90.0 95.0
White cell count (×109/L) 5 5.9 0.9 4.9 7.1 5 5.7 1.1 4.0 7.0
Lymphocytes (×109/L) 5 2.1 0.3 1.7 2.6 5 2.0 0.3 1.8 2.4
Monocytes (×109/L) 5 0.4 0.1 0.3 0.5 5 0.6 0.1 0.5 0.8
neutrophils (×109/L) 5 3.1 0.9 2.3 4.6 5 3.4 0.8 2.3 4.3
Basophils (×109/L) 5 0.0 0.1 0.0 0.1 5 0.0 0.0 0.0 0.0
eosinophils (×109/L) 5 0.2 0.1 0.1 0.4 5 0.2 0.1 0.0 0.3
Platelets (×109/L) 5 296.3 31.1 271.0 337.0 5 278.8 59.2 206.0 351.0
Biochemistry day 28
Alkaline phosphatase (µ/L) 5 58.6 10.7 47.0 69.0 5 60.8 6.8 52.0 71.0
serum alanine aminotransferase (µ/L) 5 17.4 3.0 13.0 21.0 5 25.6 18.8 10.0 58.0
Aspartate aminotransferase (µ/L) 5 21.8 4.4 17.0 29.0 5 25.0 7.3 17.0 37.0
gamma glutamyl transferase (µ/L) 5 13.4 4.3 9.0 20.0 5 14.6 5.7 10.0 24.0
Bilirubin (µmol/L) 5 11.4 4.2 7.0 17.0 5 12.6 5.3 5.0 18.0
Protein (g/L) 5 67.4 3.9 64.0 73.0 5 68.2 3.0 64.0 71.0
Albumin (g/L) 5 44.8 2.7 43.0 49.0 5 43.6 2.6 41.0 47.0
sodium (mmol/L) 5 139.4 0.9 138.0 140.0 5 139.0 1.0 138.0 140.0
Potassium (mmol/L) 5 4.0 0.2 3.7 4.2 5 4.2 0.3 3.9 4.6
chloride (mmol/L) 5 107.4 1.8 105.0 110.0 5 106.0 1.2 105.0 108.0
BUn/urea (mmol/L) 5 4.0 0.3 3.8 4.5 5 5.0 1.7 2.5 6.4
creatine (mmol/L) 5 68.6 8.5 60.0 82.0 5 78.6 18.9 64.0 111.0
Abbreviations: BUn, blood urea nitrogen; max, maximum; min, minimum; sD, standard deviation.Biologics Targets & Therapy 2011:5 submit your manuscript | www.dovepress.com
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using the 100 mg treatment only (n = 5). The multivariate 
Wilks lambda significance and the univariate significance 
were used as an indication of significant time effects, and 
the significance of the decomposition of the univariate time 
effect into a linear component was used as an   indication 
of the existence of a beneficial effect of the 100 mg treat-
ment over time. Only phagocytosis by granulocytes and 
monocytes showed a significant linear component in a 
beneficial direction over time (P = 0.038 and P = 0.014, 
respectively).
Estimated means, standard errors, and 95% confidence 
intervals for the immune responses of monocytes, granulo-
cytes, and IL-6 for the 100 mg treatment, together with the 
significance values for the Wilks lambda test for the time 
effect, the univariate test for time, and the linear component 
over time, are presented in Table 11. Phagocytosis of granu-
locytes and monocytes for the 100 mg treatment over time 
are also shown in Figure 3.
serum OrAc
The descriptive statistics for serum ORAC on days 1, 3, and 
28 are presented in Table 12. The results of the repeated-
measures analysis of variance showed that serum ORAC 
significantly increased over time (P = 0.003), but the time 
by treatment effect and the treatment main effect were non-
significant (P . 0.05). Estimated time means and the results 
of Bonferroni-adjusted pairwise comparisons are presented 
in Table 13, with time by treatment means illustrated in 
Figure 4.
Discussion
This study investigated the acute safety and immunomodula-
tory effects of a seaweed nutrient complex containing a blend 
Table 4 Lipid profile (mmol/L): means, SD, minima, and maxima by treatment arm and measurement occasion
Day 100 mg 1000 mg
N Mean SD Min Max N Mean SD Min Max
cholesterol 1 5 4.88 0.98 3.40 5.70 5 3.94 0.38 3.40 4.30
28 5 4.74 0.74 3.70 5.50 5 3.92 0.81 3.10 5.10
hDL 1 5 1.45 0.36 1.14 1.94 5 1.18 0.21 0.94 1.48
28 5 1.51 0.35 1.25 1.99 5 1.25 0.39 0.84 1.83
LDL 1 5 3.04 0.88 1.90 4.10 5 2.34 0.29 2.00 2.70
28 5 2.84 0.66 2.30 3.70 5 2.26 0.43 1.90 2.90
ratio cholesterol:hDL 1 5 3.46 0.84 2.70 4.70 5 3.40 0.38 2.80 3.80
28 5 3.22 0.70 2.30 4.20 5 3.24 0.40 2.80 3.90
Triglycerides 1 5 0.90 0.34 0.50 1.40 5 0.90 0.34 0.50 1.40
28 5 0.86 0.37 0.40 1.40 5 0.84 0.29 0.40 1.10
Abbreviations: hDL, high-density lipoprotein; LDh, low-density lipoprotein; max, maximum; min, minimum; sD, standard deviation.
Table 5 Blood safety measure: P-values for repeated measures 
analysis of variance
Measure Time Time by  
treatment
Treatment
red cell count (×1012/L) 0.079 0.897 0.441
hemoglobin (g/L) 0.309 0.916 0.445
hematocrit (%) 0.172 0.772 0.307
Mean corpuscular  
volume (fL)
0.608 0.608 0.946
White cell count (×109/L) 0.419 0.846 0.873
Lymphocytes (×109/L) 0.767 0.557 0.319
Monocytes (×109/L) 0.276 0.367 0.054
neutrophils (×109/L) 0.567 0.506 0.764
eosinophils (×109/L) 1.000 0.373 0.788
Platelets (×109/L) 0.442 0.741 0.698
Alkaline phosphatase (µ/L) 0.065 0.880 0.683
serum alanine  
aminotransferase (µ/L)
0.089 0.407 0.359
Aspartate  
aminotransferase (µ/L)
0.065 0.428 0.537
gamma glutamyl  
transferase (µ/L)
0.825 0.207 1.000
Bilirubin (µmol/L) 0.175 0.478 0.806
Protein (g/L) 0.591 0.591 0.564
Albumin (g/L) 0.870 0.626 0.576
sodium (mmol/L) 0.187 0.412 0.849
Potassium (mmol/L) 0.170 0.220 0.035
chloride (mmol/L) 0.368 0.368 0.291
BUn/urea (mmol/L) 0.227 0.302 0.429
creatinine (mmol/L) 0.847 0.347 0.306
Abbreviation: BUn, blood urea nitrogen.
Table  6  cholesterol  and  triglycerides:  P-values  for  repeated 
measures analysis of variance
Outcome Time Time by treatment Treatment
cholesterol  0.627 0.714 0.089
hDL 0.158 0.946 0.230
LDL 0.403 0.715 0.105
ratio cholesterol:hDL 0.087 0.707 0.959
Triglycerides 0.561 0.906 0.961
Abbreviations: hDL, high-density lipoprotein; LDh, low-density lipoprotein.Biologics Targets & Therapy 2011:5 submit your manuscript | www.dovepress.com
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Table 7 immune function means, sD, minima, and maxima by treatment arm and measurement occasion
Outcome Day 100 mg 1000 mg
N Mean SD Min Max N Mean SD Min Max
T cells  1
3
28
5
5
5
2.01
2.19
1.93
0.32
0.36
0.35
1.77
1.83
1.63
2.55
2.73
2.49
5
5
5
1.93
1.96
1.90
0.45
0.35
0.40
1.58
1.45
1.47
2.55
2.31
2.49
B cells cD19  1
3
28
5
5
5
0.24
0.24
0.18
0.08
0.09
0.08
0.18
0.13
0.10
0.38
0.33
0.31
5
5
5
0.25
0.23
0.20
0.08
0.06
0.06
0.16
0.17
0.16
0.38
0.33
0.31
helper T cells 1
3
28
5
5
5
1.30
1.44
1.28
0.19
0.43
0.24
0.99
0.88
0.86
1.46
1.93
1.41
5
5
5
1.28
1.30
1.28
0.25
0.20
0.18
0.92
1.02
0.97
1.57
1.54
1.41
cytotoxic T cells  1
3
28
5
5
5
0.71
0.76
0.66
0.33
0.26
0.28
0.41
0.45
0.41
1.19
1.10
1.11
5
5
5
0.66
0.71
0.65
0.31
0.24
0.28
0.41
0.45
0.41
1.19
1.10
1.11
natural killer cells  1
3
28
5
5
5
0.28
0.40
0.26
0.10
0.18
0.06
0.16
0.19
0.20
0.39
0.67
0.33
5
5
5
0.24
0.35
0.24
0.11
0.21
0.09
0.06
0.08
0.08
0.33
0.67
0.32
Total T cells 1
3
28
5
5
5
32.32
28.96
34.56
9.19
9.41
10.47
18.80
17.10
16.70
42.30
40.60
44.00
5
5
5
30.76
29.04
33.56
5.27
8.51
6.19
24.20
20.50
28.30
38.70
41.10
44.00
Activation cD4 1
3
28
5
5
5
30.16
27.00
31.34
9.11
9.38
9.77
17.10
15.20
15.40
40.30
38.70
40.50
5
5
5
26.06
24.64
30.30
6.01
8.84
6.36
17.70
15.00
23.10
34.50
38.70
40.50
Activation cD8 1
3
28
5
5
5
35.48
29.08
39.42
11.38
11.37
13.53
18.30
14.80
16.20
46.40
42.70
51.60
5
5
5
35.68
31.22
36.56
4.51
9.17
9.07
30.40
20.10
29.50
41.60
40.40
51.60
granulocyte 1 5 50.92 4.43 44.71 55.62 5 59.87 5.73 49.83 64.38
Phagocytosis 3
28
5
5
52.46
55.85
8.27
7.66
41.64
45.13
63.16
65.10
5
5
63.15
62.52
9.27
4.71
47.18
55.75
69.11
67.76
Monocyte  1 5 37.79 5.57 31.02 44.58 5 45.53 6.98 36.35 53.08
Phagocytosis 3
28
5
5
42.74
50.40
6.73
7.18
33.52
41.05
50.91
59.97
5
5
48.27
51.99
4.64
4.76
40.00
45.02
50.93
56.96
iFn-gamma  1
3
28
5
5
5
9862
8302
7327
8943
6829
7247
0
0
0
19,094
15,336
15,336
5
5
5
1412
1641
1258
898
623
574
292
732
314
2490
2239
1777
iL-6  1
3
28
5
5
5
20,955
22,108
16,022
5388
6696
5181
17,541
15,476
10,955
30,374
33,042
22,957
5
5
5
23,509
24,195
18,864
6858
4894
5073
15,476
20,105
13,805
31,678
32,695
27,079
TnF-alpha  1
3
28
5
5
5
3282
6150
4337
1041
3413
1998
1832
1832
1409
4343
11,221
6433
5
5
5
2564
2186
4435
1214
1380
1245
919
742
2924
4242
4067
6373
iL-10  1
3
28
5
5
5
40.40
47.80
29.20
21.10
17.54
20.56
18.00
28.00
0.00
66.00
73.00
57.00
5
5
5
41.20
49.00
29.80
8.47
35.43
23.69
28.00
18.00
0.00
49.00
105.00
64.00
iL-2  1
3
28
5
5
5
25.80
28.00
20.00
15.35
3.74
19.39
0.00
22.00
0.00
41.00
32.00
52.00
5
5
5
20.20
27.40
15.20
11.45
9.48
10.80
0.00
16.00
0.00
28.00
41.00
30.00
iL-4  1
3
28
5
5
5
0.00
20.60
11.40
0.00
29.00
25.49
0.00
0.00
0.00
0.00
61.00
57.00
5
5
5
0.00
8.00
14.40
0.00
17.89
13.16
0.00
0.00
0.00
0.00
40.00
25.00
Abbreviations: iFn, interferon; iL, interleukin; max, maximum; min, minimum; sD, standard deviation; TnF, tumor necrosis factor.Biologics Targets & Therapy 2011:5 submit your manuscript | www.dovepress.com
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of extracts from three brown algae species (Fucus vesiculosis, 
Macrocystis pyrifera, and Laminaria japonica) plus vitamin 
B6, zinc, and manganese. The preparation was demonstrated 
to be safe over the course of the study. Adverse events expe-
rienced during the study were mild and self-limiting; there 
were no changes in hemopoetic, hepatic, or renal functions or 
in cholesterol and triglycerides of clinical significance; and 
the vital signs of participants remained healthy. This follows 
a study using the same preparation in 12 individuals with 
osteoarthritis over 12 weeks, which also demonstrated acute 
safety of the preparation.30
This study did not show a dose response effect in the 
efficacy outcomes between the two doses of the study prepa-
ration (100 mg and 1000 mg), as no discernible differences 
in any immune measure or the serum ORAC were found 
in the primary analysis. This may be explained by one of 
two possibilities. Firstly, the maximum effect was reached 
by the 100 mg dose, and no further response was possible 
at higher doses. Secondly, the study was not powered to 
discern such differences, which is a type II error. Given the 
small study numbers, it is more likely to be a type II error, 
and a larger study needs to be undertaken to determine dose 
responsiveness. Trends worthy of pursuit in a larger study 
include near-significant changes (P , 0.1) between treat-
ments averaged over time, which were found for IFN-γ, 
TNF-α, and phagocytosis by granulocytes.
The study did find significant time effects, suggesting 
that the combined results from both doses showed signifi-
cant change over time for B cells (CD19), cytotoxic T cells, 
phagocytosis by monocytes, and IL-6. Comparisons for the 
significant time response showed that, between day 1 and 
day 28, B cells and IL-6 decreased significantly, phagocytosis 
by monocytes increased significantly, and cytotoxic T cells 
increased then decreased to day 28. Total T cells, activation 
CD4, activation CD8, NK cells, and IL-2 showed a near-
significant change over time (P , 0.1).
The separate repeated-measures analyses on phagocytosis 
by monocytes, phagocytosis by granulocytes, and IL-6 using 
only the 100 mg treatment demonstrated that phagocytosis 
Table  8  immune  function  outcomes:  P-values  for  repeated 
measures analysis of variance
Immune function 
outcome
Time Time 
by treatment
Treatment
T cells 0.077 0.409 0.609
B cells cD19 0.003 0.486 0.900
helper T cells 0.440 0.576 0.727
cytotoxic T cells 0.018 0.498 0.837
natural killer cells 0.098 0.896 0.667
Total T cells 0.127 0.853 0.871
Activation cD4 0.052 0.313 0.631
Activation cD8 0.068 0.703 0.977
granulocyte 
phagocytosis
0.038 0.496 0.060
Monocyte 
phagocytosis
0.005 0.320 0.168
iFn-gamma 0.490 0.379 0.059
iL-6 0.004 0.955 0.477
TnF-alpha 0.203 0.117 0.087
iL-4 0.901 0.495 0.605
iL-10 0.227 0.999 0.935
iL-2 0.077 0.699 0.569
Abbreviations: iFn, interferon; iL, interleukin; TnF, tumor necrosis factor.
Table 9 estimated time means and multiple comparison results for B cells (cD19), cytotoxic T cells, monocyte phagocytosis, and iL-6
Day Mean SD  Lower 95% Upper 95% Multiple comparisons
B cells  1 0.244 0.026 0.183 0.305 1 versus 28 P = 0.003
(cD19) 3 0.236 0.024 0.180 0.292 3 versus 28 P = 0.069
28 0.193 0.023 0.140 0.246
cytotoxic T cells 1 0.686 0.102 0.451 0.921 1 versus 28 P = 0.018
3 0.736 0.079 0.553 0.919 3 versus 28 P = 0.024
28 0.653 0.089 0.448 0.858 1 versus 3 P = 0.032
Monocyte phagocytosis 1 41.661 1.996 37.058 46.264 1 versus 28 P = 0.002
3 45.506 1.828 41.290 49.722 3 versus 28 P = 0.031
28 51.194 1.927 46.751 55.637
iL-6 1 22,232 1950 17,735 26,729 1 versus 28 P = 0.011
3 23,152 1854 18,875 27,428 3 versus 28 P = 0.003
28 17,443 1621 13,703 21,182
Abbreviations: iL, interleukin; sD, standard deviation.Biologics Targets & Therapy 2011:5 submit your manuscript | www.dovepress.com
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by both granulocytes and monocytes showed a significant 
linear component.
Serum ORAC similarly did not show a dose response 
effect between the two treatments but did demonstrate a 
significant time effect between day 1 and day 3 with the 
two treatments combined. This represented a 25% increase 
in serum ORAC by day 3, which is consistent with other 
natural antioxidants such as vitamin C and spinach.31 It has 
been suggested that sulfated polysaccharides from edible 
seaweeds could be used as natural antioxidants in the food 
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Figure 1 Mean by treatment over time for B cells (cD19) (A), cytotoxic T cells (B), monocyte phagocytosis (C), and interleukin-6 (D).
Table 10 estimated time and treatment means for granulocyte phagocytosis
Treatment Day Mean SD  Lower 95% Upper 95% Comparisons
100 mg 1 50.92 2.29 45.64 56.21
3 52.46 3.93 43.40 61.52
28 55.85 2.85 49.29 62.41
1000 mg 1 59.87 2.29 54.59 65.15
3 63.15 3.93 54.09 72.21
28 62.52 2.85 55.96 69.08
combined 1 55.38 1.62 51.66 59.13 1 versus 3 P = 0.563
3 57.80 2.78 51.40 64.21 1 versus 28 P = 0.025
28 59.19 2.01 54.55 63.83
100 mg combined 53.08 2.84 46.54 59.62 P = 0.060
1000 mg combined 61.85 2.84 55.31 68.39
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industry.11 The antioxidant effects of manganese in the blend 
should also be considered as a contributor to this increased 
activity. However, the pattern of the results showed that the 
1000 mg dose continued to increase in activity, whereas 
the 100 mg dose started to decline. Given that the level of 
manganese (and B6 and zinc) was the same for both doses, 
this suggests that seaweed constituents are responsible for at 
least part of the effect. This role of seaweed as an antioxidant 
is worth exploring in further research.
Defense against invasive pathogens and the elimination 
of defective cells are coordinated between the innate and 
adaptive (specific) immune systems. The nonspecific innate 
immune system attacks pathogens quickly. This response 
includes NK cells and phagocytic cells. After a pathogen 
or defective cell is ‘recognized’, this response is backed by 
antigen-specific cells such as cytotoxic T cells. NK cells 
help to contain viral infections, and a lack of NK cells, either 
intrinsic or stress induced, is associated with vulnerability 
to viral infections.32 In this study, data at day 3 indicated 
significant increases in cytotoxic T cells and near-significant 
increases in NK cells. This short-term increase in cytotoxic T 
cells was accompanied by a continual increase in phagocyto-
sis by monocytes and the near-significant increase in phago-
cytosis by granulocytes over the 28-day period. Monocytes 
and granulocytes are a critical part of the immune system 
and are responsible for the phagocytosis and destruction of 
foreign bodies such as bacteria.31 Overall, these data suggest 
an immune-priming role of the nutrient seaweed complex, 
which is worthy of further exploration. The significant linear 
component over time for phagocytosis by both monocytes and 
granulocytes when the 100 mg data were analyzed alone con-
firms that this dosage has an immunomodulatory effect.
In addition to immune modulation, the complex has 
potential anti-inflammatory activity, exhibited by the 
significant decrease in IL-6 between day 1 and day 28. 
It is important to note that the measurement taken in this 
study was not of absolute serum levels of IL-6, which 
remains to be elucidated, but the amount of IL-6 produced 
by challenged cells. IL-6 is a multifunctional cytokine 
that is produced by many cell types, including leukocytes 
and endothelial cells. Levels of IL-6 were associated with 
increased cardiovascular risk in the Women’s Health 
Study.33,34 The levels of IL-6 were increased in women with 
cardiovascular events, and women with median levels of 
total cholesterol had increased risk if they had high levels 
of IL-6. This potential anti-inflammatory effect deserves 
further investigation, as any agent capable of reducing 
IL-6 may confer substantive health benefits.
Serum antioxidant capacity increased significantly over 
the course of the study. Long-term increases in serum anti-
oxidant status are correlated with improved health and with 
lower levels of IL-6,33 consistent with this study. The marked 
effect this preparation demonstrated in osteoarthritis30 with 
the 1000 mg dose reducing the symptoms by 52%, which 
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Figure 2 Mean by treatment over time for granulocyte phagocytosis.
Table 11 Estimated time means and significance of component effects for 100 mg treatment on specific immune responses
Immune response Day Mean SD  Lower 95% Upper 95% Multivariate 
Wilks lambda 
P
Univariate 
time 
P
Linear 
component 
P
Monocyte phagocytosis 1
3
28
37.79
42.74
50.40
2.49
3.01
3.21
30.87
34.38
41.48
44.71
51.10
59.31
0.068 0.006 0.014
granulocyte phagocytosis 1
3
28
50.92
52.46
55.85
1.98
3.70
3.43
45.42
42.19
46.333
56.42
62.72
65.37
0.125 0.147 0.038
Production iL-6  1
3
28
20,955.0
22,108.0
16,021.6
2409.7
2994.5
2317.0
14,264.6
13,794.1
9588.6
27,645.4
30,421.9
22,454.6
0.177 0.032 0.061
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is equivalent to the effect expected from a nonsteroidal 
  anti-inflammatory drug,35 coupled with the effect on IL-6 and 
serum antioxidant capacity, provides consistent evidence of 
anti-inflammatory activity.
The outcome measure for the cholesterol ratio showed 
near-significant beneficial change over time (P , 0.10), which 
may reflect potential pharmacological activity. A number of 
seaweed species29–32 have been found to have hypolipidemic 
effects, which may well deserve further study.
The role of the added nutrients in the preparation cannot 
be assessed independently, and the amount they contributed 
to the effects of the preparation is unknown. Adequate 
intake of micronutrients is required for the immune system 
to function efficiently,36,37 and specific nutrients were added 
to the complex to ensure their availability. Zinc is known 
to play a role in the immune system; however, its precise 
roles and mechanisms have not yet been resolved.38 Vita-
min B6 deficiency is known to depress both humoral and 
cell-mediated immune responses.39 A dose of 50 mg daily, 
equivalent to this study, significantly increased T-lymphocyte 
and T-helper cell numbers and the percentage of T-suppressor 
cells in 14 days in a group of critically ill intensive care 
patients40 who were likely to have some degree of immuno-
compromise. Although we did not see these changes in this 
study, it is likely that the participants had adequate vitamin 
B6 intake, given that substantially increased doses of vitamin 
B6 do not produce added benefits.39
A limitation of the study design was that the 100 mg 
dose was delivered once per day as a single capsule (in the 
  morning), and the 1000 mg dose was delivered twice per day 
(two 250 mg capsules morning and night, four capsules total 
per day). Differences in the number of capsules and the dos-
ing schedule between the groups may have had a bearing on 
the observed outcomes. Other areas of potential bias include 
gender and diet. Participants in this study comprised nine 
females and one male, placing an emphasis on the potential 
effects of female physiology, which may not be generaliz-
able to male physiology. The participants’ background diets 
need to be assessed, as they may vary widely in the intake of 
seaweed products and land-based fruits and vegetables, which 
may have an effect on serum ORAC and other laboratory 
parameters. Further rigorous study needs to eliminate these 
areas of potential bias.
One shortcoming of seaweed extract and fucoidan 
research to date has been the lack of data from clinical 
settings and in vivo models, especially at clinically viable 
dosage levels. The methods used to prepare extracts of 
fucoidan from seaweed vary from laboratory preparations to 
commercial extraction methods, where heat and ethanol may 
be used during extraction and possibly solvent precipitation. 
The differences in extraction methods may result in 
inconsistent biological activity. Lowering the molecular 
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Figure 3 Means over time for 100 mg treatment for phagocytosis by monocytes 
(A) and granulocytes (B).
Table 12 serum OrAc (µmol Trolox equivalents/L): means, sD, minima, and maxima by treatment arm and measurement occasion
Outcome Day 100 mg 1000 mg
N Mean SD Min Max N Mean SD Min Max
serum OrAc  1 5 612.40 92.65 483 730 5 697.20 64.59 635 805
3 5 802.60 134.05 575 907 5 836.20 115.25 725 1,011
28 5 764.40 253.28 575 1,208 5 890.40 132.29 746 1,025
Abbreviations: max, maximum; min, minimum; OrAc, oxygen radical absorbance capacity; sD, standard deviation.Biologics Targets & Therapy 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
58
Myers et al
size of fucoidans by more extensive chemical processing 
has been shown to inactivate in vivo enzyme inhibitory 
activity against phospholipase-A2.41 For this reason, it has 
been postulated that the novel aqueous extraction process 
used in the development of this study medication, which 
produces largely unaltered fucoidan fractions, may be 
more clinically effective. Further research is necessary 
to determine the best method for delivering therapeutic 
benefits from seaweeds.
This study was an exploratory study, and it is important 
that it is not over-interpreted. The most significant limitation 
was that it was an open-label combined Phase I and II trial 
and therefore was subject to potential bias, which would be 
reduced by the use of randomization and blinding. This study 
aimed to explore the potential bioactivity of the preparation on 
immune function and determine a safe and effective dose that 
can be used in a more rigorous clinical trial design. This study 
achieved these aims and demonstrated that the study medication 
at 100 mg has the potential to act as an immunomodulator.
Conclusion
A complex containing a blend of seaweed extracts and nutri-
ents when taken orally over 4 weeks was demonstrated to 
be safe to use over the study period at the doses tested. The 
100 mg dose was shown to be immunomodulatory, and this 
pharmacological activity now needs to be demonstrated in 
a Phase III randomized controlled trial with an appropriate 
sample size.
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